What makes the four biotech penny stocks highlighted in today’s article ones to watch this month? They are all releasing key information which could serve… Read More »Potential June Catalysts Make These 4 Biotech Penny Stocks To Watch
While the Human Genome Project was declared complete 20 years ago, the mapping of the human genome was not truly complete. As the author of… Read More »Filling In The Missing Parts Of The Genetic Map Could Translate Into Huge Gains For This Biotech
This month in biotech, “Some of the industry’s biggest players are waiting for clinical trial results and decisions from the FDA that could send their… Read More »Reading The Tea Leaves On Some Major Biotech Catalysts This Month
As the deadline for the FDA to decide whether to approve it nears, Biogen’s much-debated Alzheimer’s drug aducanumab faces its moment of truth – and… Read More »A Moment Of Truth For Biogen’s Alzheimer’s Drug – And The Biotech Sector
After being the target of much investor attention amid the COVID-19 pandemic, many investors have rotated out of the pricey pharmaceutical sector over the past… Read More »These 3 Pharmaceutical Stocks Look Significantly Undervalued
Due in part to the American Society of Clinical Oncology’s big cancer conference, June is often a popular month for M&A activity in the biotech… Read More »Why Biotech M&A Activity Could Heat Up In June – And Some Potential Acquisition Targets
“I don’t remember ever being more excited about a long-term investment theme,” declares the author of today’s article in regards to genomics. Going further, he… Read More »Building A Biotech Barbell
“While the start of the calendar year is often prime time for U.S. Food and Drug Administration (FDA) events and trial data to be released,… Read More »With Major Catalysts This Summer, These 8 Biotech Stocks Could Heat Up
From March 2020 to February 2021, biotech stocks were the darling of the stock market. Since February, however, investor sentiment on the biotech industry has… Read More »Buy The Biotech Dip?
After a down year for M&A activity in the biotech industry, 2021 is expected to see greater deal volume – and the four biotechs highlighted… Read More »Bought Out Or Standalone, These 4 Potential Biotech Takeover Targets Are Attractive Picks